We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · April 20, 2021

Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents
J. Clin. Oncol 2021 Apr 06;[EPub Ahead of Print], P Dürr, K Schlichtig, C Kelz, B Deutsch, R Maas, MJ Eckart, J Wilke, H Wagner, K Wolff, C Preuß, V Brückl, N Meidenbauer, C Staerk, A Mayr, R Fietkau, PJ Goebell, F Kunath, MW Beckmann, A Mackensen, MF Neurath, M Pavel, F Dörje, MF Fromm

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading